58 F. Supp. 3d 391
S.D.N.Y.2014Background
- Plaintiff Jesse McDowell sued Eli Lilly alleging Cymbalta’s label failed to warn adequately of discontinuation/withdrawal risks and asserted related design, negligence, warranty, fraud, and consumer‑fraud claims.
- FDA approved Cymbalta in 2004; the Physician Package Insert in effect in 2008 warned of discontinuation symptoms, listed specific symptoms, recommended gradual tapering, and noted some events occurred “at a rate greater than or equal to 1%” in placebo‑controlled trials.
- A 2005 Journal of Affective Disorders article (Perahia et al.) — based on nine Lilly‑sponsored trials — reported higher discontinuation symptom rates in duloxetine patients (e.g., ~44% in short‑term trials, ~50% in longer trials by plaintiff’s reading).
- Plaintiff experienced alleged discontinuation symptoms after stopping Cymbalta in 2012; most symptoms resolved by 2013, but he claims ongoing fear of recurrence.
- The prescriber (Nurse Practitioner Joan Caruana) testified she was generally aware from clinical experience of discontinuation risks for SSRIs/SNRIs, recognized the symptoms listed on the label, and said the label’s “≥1%” language did not mean only a 1% chance; she also testified she would have chosen another drug only if Cymbalta’s withdrawal were as severe as Effexor.
- Eli Lilly moved for summary judgment; the court granted the motion, dismissing all claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Adequacy of warning to prescribing physicians | McDowell: label misleading/insufficient because it omitted higher frequencies (44–50%) reported in clinical data and used a “≥1%” threshold that downplays risk | Lilly: label complied with FDA requirements, listed specific symptoms, noted higher rates vs. placebo, and advised tapering; frequency cutoffs are standard | Warning was adequate as a matter of law — specific symptoms, seriousness, and tapering guidance satisfied New York standard (Martin) |
| Causation — did inadequate warning proximately cause injury? | McDowell: had prescriber known trial frequencies she might have chosen a different drug; thus warning caused injury | Lilly: prescriber had independent knowledge/experience of discontinuation risks and was not misled by the label; that independent knowledge breaks causal chain | No proximate cause — prescriber’s independent awareness insulated Lilly from liability |
| Whether frequency disclosure is required in label | McDowell: label should have disclosed trial percentages (44–50%) | Lilly: no legal duty to include specific adverse‑event frequencies; FDA format using frequency thresholds is proper | Court: courts have not required specific frequency disclosure; label’s methodology (≥1% cutoff) is acceptable |
| Bar to related claims (design, warranty, fraud, consumer fraud) | McDowell: independent causes of action survive even if warning adequate | Lilly: adequacy of warnings defeats all related claims; New York law bars design‑defect claims for prescription drugs accompanied by adequate warnings | Court: all related claims barred because warning adequate and proximate causation not shown |
Key Cases Cited
- Martin v. Hacker, 83 N.Y.2d 1 (New York 1993) (manuf.’s duty to warn runs to prescribing physician; adequacy of warning may be decided as matter of law)
- Alston v. Caraco Pharm. Labs., 670 F. Supp. 2d 279 (S.D.N.Y. 2009) (physician‑directed warning listing withdrawal symptoms held adequate despite lacking precise frequencies)
- Ohuche v. Merck & Co., 903 F. Supp. 2d 143 (S.D.N.Y. 2012) (treating physician’s independent awareness of vaccine adverse reactions negates proximate cause)
- Wolfgruber v. Upjohn Co., 72 A.D.2d 59 (N.Y. App. Div. 1979) (prescription drug with adequate warnings is not defective)
- Glucksman v. Halsey Drug Co., 160 A.D.2d 305 (N.Y. App. Div. 1990) (physician’s decision or knowledge can sever causal chain between manufacturer warning and patient injury)